We searched the Medline database for articles and abstracts published in English between Jan 1, 1996 and July 2, 2010 with the search terms “polypharmacy”, “neoplasms”, “aged”, “drug interactions”, and “information systems”. We manually searched reference lists from identified articles, our own files, and recent reviews to identify additional articles. We also reviewed relevant conference abstracts. Studies and review articles were included on the basis of their relevance to the specific topic
ReviewPolypharmacy in elderly patients with cancer: clinical implications and management
Introduction
Cancer incidence increases with age, and because the proportion of the population that is elderly is growing, the absolute number of elderly patients (variously defined as >65 years or >70 years) with cancer continues to increase. In the UK, 74% of new cancer diagnoses in 2006 were in people aged 60 years or older, with more than a third occurring in those aged 75 years or older.1 By 2030, about 70% of all cancers in USA will be diagnosed in older adults.2 In the heterogeneous elderly population, many patients can be medically fit until the diagnosis of cancer. However, chronic medical disorders such as cardiovascular diseases (eg, hypertension, heart failure, and coronary artery disease), cerebrovascular disease, arthritis, and diabetes are common in the general elderly population. Therefore, not only are comorbidities common in older people who are newly diagnosed with cancer, but also many of these patients take drugs for primary or secondary disease prophylaxis and treatment, and possibly also take other self-prescribed medicines.3 To tailor treatment decisions on the basis of factors other than age, there is an increasing amount of evidence to suggest the benefits of incorporation of a comprehensive geriatric assessment for elderly patients who are newly diagnosed with cancer.4 Review of patients' medications before starting cancer treatment is an integral part of the assessment, and such reviews have identified potential pre-existing drug-related issues.4, 5 Addition of chemotherapy and supportive drugs to prevent side-effects or manage symptoms to existing polypharmacy can place older patients with cancer at risk of drug interactions that might alter efficacy or increase toxic effects.4, 6
In this Review, we examine the clinical implications of polypharmacy in elderly people diagnosed with cancer and review different procedures for obtaining of complete drug histories, including prescribed and non-prescribed medicines. We examine the accuracy of present methods for assessment of patients' medications for drug interactions and possible clinical significance. We present practical recommendations for drug management of elderly patients with cancer.
Section snippets
Overview of polypharmacy
As an indication of global interest in this topic, we identified nearly 500 citations with a search of the Medline database for “polypharmacy”. Research and reviews on polypharmacy cross many specialty areas from psychiatry to cardiology, and chronic diseases such as diabetes and epilepsy. The prevalence of polypharmacy in older patients ranges from 13% to 92%.7 In oncology, older patients with cancer are now recognised as a risk group.5
Polypharmacy has many definitions but commonly refers to
Polypharmacy in patients with cancer
Various international studies3, 5, 12, 13, 14 have suggested that polypharmacy is common in elderly patients with cancer (table 1). An exploratory study in the UK3 reported a median of seven medications (IQR 1–17) were being taken by 100 patients who had metastatic cancer and a median age of 73 years. 81 patients were taking preventive medications including antihypertensives, lipid-lowering drugs, antiplatelet drugs, anticoagulants, and bisphosphonates (for non-cancer indications). Of the 112
Adverse drug reactions
In older people, including those with cancer, there are various negative outcomes that can result from polypharmacy, including adverse drug reactions, drug interactions, and increased health-care costs.
Data from the non-cancer setting suggest that rates of hospital admission due to adverse drug reactions are highest in the oldest age groups,19 with a median prevalence of 10·7% in patients older than 60 years, 6·3% in adults aged 17–59 years, and 4·1% in children aged 16 years or younger; the
Assessment of elderly patients with cancer
Optimisation of treatment in elderly patients needs a collaborative approach including primary care and specialist doctors, and other health professionals such as clinical pharmacists and nurses. An integral part of the comprehensive geriatric assessment of older patients with newly diagnosed cancer is a medication review of all prescription, over-the-counter, and herbal products.4 In some countries, routine medication reconciliation, in which a complete list of a patient's medications is
Drugs interactions resources
Once a patient's complete medication list has been established, either all patients or those at high risk for drug interactions need to be screened.24 Many resources are available to check for interactions between a patient's treatment drugs and proposed anticancer and supportive medications.24 Numerous articles summarising drug interaction information have been published, and many provide tables of interactions that are clinically relevant.6, 19, 20, 22, 23, 25, 26 However, investigation of
Polypharmacy—practical solutions
Recognition of polypharmacy is the first step towards prevention.46 Rational discontinuation of drugs in older adults is a logical component of management of polypharmacy,59 and is recommended as part of a comprehensive geriatric assessment in such patients with cancer.4 Discussion with the patient and consideration of overall quality of life is essential. The selection of appropriate pharmacotherapy for elderly patients is a challenging and complex process,60 even when cancer is not involved,
Search strategy and selection criteria
References (61)
- et al.
Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients
Ann Oncol
(2009) - et al.
Drug–drug interactions in oncology: why are they important and can they be minimized?
Crit Rev Oncol Hematol
(2005) Understanding and preventing drug interactions in elderly patients
Crit Rev Oncol Hematol
(2003)- et al.
Drug interactions in oncology
Lancet Oncol
(2004) - et al.
Drug interactions in oncology: how common are they?
Ann Oncol
(2009) - et al.
Potential drug interactions in elderly cancer patients
Crit Rev Oncol Hematol
(2011) - et al.
Drug interactions between chemotherapeutic regimens and antiepileptics
Clin Ther
(2008) - et al.
An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project
Support Care Cancer
(2009) - et al.
Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists
Clin Ther
(2009) - et al.
Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions
Am J Geriatr Pharmacother
(2009)
Organization of the clinical activity of Geriatric Oncology: report of a SIOG (International Society of Geriatric Oncology) task force
Crit Rev Oncol Hematol
Infancy of an Australian geriatric oncology program—characteristics of the first 200 patients
J Geriatr Oncol
Medication reconciliation in ambulatory oncology
Jt Comm J Qual Patient Saf
Black box warning contraindicated comedications: concordance among three major drug interaction screening programs
Ann Pharmacother
Tiering drug–drug interaction alerts by severity increases compliance rates
J Am Med Inform Assoc
Appropriate prescribing in elderly people: how well can it be measured and optimised?
Lancet
Concomitant medications in cancer patients: should we be more active in their management?
Ann Oncol
Demographic facts for the world population
Future of cancer incidence in the United States: burdens upon an aging, changing nation
J Clin Oncol
The treatment of comorbidities in older patients with metastatic cancer
Support Care Cancer
Comprehensive geriatric assessment for older patients with cancer
J Clin Oncol
Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study
Drugs Aging
Drug interactions in cancer therapy
Nat Rev Cancer
Polypharmacy in older adults with cancer
Oncologist
Merriam-Webster online
Polypharmacy in the elderly: a literature review
J Am Acad Nurse Pract
Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems
Br J Clin Pharmacol
Updating the Beers criteria for potentially inappropriate medication use in older adults
Arch Intern Med
Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation
J Oncol Pharm Pract
Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management
J Clin Pharm Ther
Cited by (201)
Geriatric Phenotypes and Their Impact on Oral Health
2023, Clinics in Geriatric MedicineInhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions
2023, Toxicology and Applied PharmacologyEvaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive study
2022, Journal of Geriatric OncologyCitation Excerpt :We, therefore, evaluated the incidence of seizures and, as anticipated, fewer older participants reported seizures compared to younger adults, who tend to have slower-growing tumors [46]. Polypharmacy is common in older patients with cancer and leads to additional toxicities, drug interactions, and increased costs [47]. Decreased renal and hepatic function alters drug pharmacology, typically decreasing drug clearance, and is associated with biological aging [48].
Living with a blood cancer in later life: The complex challenges and related support needs of adults aged 75 and older
2023, Palliative and Supportive CarePrediction of 30-day, 90-day, and 1-year mortality after colorectal cancer surgery using a data-driven approach
2024, International Journal of Colorectal Disease